Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
10 Mar 2021
10 Mar 2021
Historique:
entrez:
24
3
2021
pubmed:
25
3
2021
medline:
25
3
2021
Statut:
epublish
Résumé
The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV-2 infection. CBD and its metabolite, 7-OH-CBD, but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after cellular infection, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD induces interferon expression and up-regulates its antiviral signaling pathway. A cohort of human patients previously taking CBD had significantly lower SARS-CoV-2 infection incidence of up to an order of magnitude relative to matched pairs or the general population. This study highlights CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for SARS-CoV-2 at early stages of infection.
Identifiants
pubmed: 33758843
doi: 10.1101/2021.03.10.432967
pmc: PMC7987002
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI127518
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM119840
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA219815
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI137514
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM121735
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI134980
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002389
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014599
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA184494
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Cell. 2021 Jan 7;184(1):106-119.e14
pubmed: 33333024
J Neurosci. 2013 Jun 12;33(24):9998-10010
pubmed: 23761895
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
Nat Commun. 2020 Jun 24;11(1):3202
pubmed: 32581217
Cell. 2021 Jan 7;184(1):92-105.e16
pubmed: 33147445
Adv Virus Res. 2011;81:85-164
pubmed: 22094080
iScience. 2020 Jun 26;23(6):101212
pubmed: 32512386
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):95-99
pubmed: 33476315
Nat Commun. 2021 Feb 2;12(1):743
pubmed: 33531496
Sci Rep. 2021 Jan 14;11(1):1462
pubmed: 33446817
Toxicol Appl Pharmacol. 2019 Nov 1;382:114713
pubmed: 31437494
Front Immunol. 2020 May 15;11:1061
pubmed: 32574262
J Med Chem. 2020 Nov 12;63(21):12137-12155
pubmed: 32804502
Mol Cancer Ther. 2016 Sep;15(9):2119-29
pubmed: 27390344
Cell. 2021 Jan 7;184(1):120-132.e14
pubmed: 33382968
Virology. 2006 Jan 5;344(1):119-30
pubmed: 16364743
FASEB J. 2020 Jan;34(1):41-65
pubmed: 31914647
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45
pubmed: 26553804
Viruses. 2020 May 06;12(5):
pubmed: 32384820
F1000Res. 2019 Feb 28;8:
pubmed: 30854190